At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 19 enrolled
Drug / intervention
Suvorexant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers
In Brief
A Phase 4 clinical trial evaluating Suvorexant and Placebo for Sleep Disorder, Shift-Work. Completed, enrolled 19 participants across 1 site.
Detailed Summary
The purpose of this study is to test the hypothesis that ingestion of the wake-inhibiting drug suvorexant 30 minutes prior to daytime sleep initiation in individuals working overnight shifts will significantly improve both objective (total sleep time, sleep efficiency, wake after sleep onset) and subjective (sleep quality) measures of daytime sleep.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSleep Disorder, Shift-Work
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, Stanford University
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartFeb 2016
Primary CompletionAug 2019
TodayJul 2026
First PostedJul 8, 2015
Enrollment StartFeb 1, 2016
Primary CompletionAug 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 11.0 years ago
Interventions
Suvorexantdrug
Placebodrug